一、計畫目標
 

為超前部署重點特色領域措施—布局產業前瞻先期技術,依第十一次全國科學技術會議,國科會推動「產業創新人才海外培訓計畫」(X Talent,以下簡稱「本計畫」),以延續原博士創新之星計畫(LEAP)培育創新創業人才之精神,並配合政府推動之「六大核心戰略產業」,選送臺灣產學創新種子人才赴海外研習,以因應美中貿易戰及後疫情時代的產業轉型及新興產業發展需求,希冀種子人才返國後協助產業創新布局及發展,讓臺灣在全球科技戰略布局,精準掌握市場先機,在未來成為全球經濟成長關鍵的力量。


二、徵求對象
 

有熱忱貢獻臺灣產業創新發展之高階人才,對於海外企業之前瞻技術、商業模式、國際策略布局等有興趣,積極拓展自己的人脈、主動探索未知領域知識,並能與跨文化、跨領域之專業人才互動良好。


三、申請資格

 

  1. 國籍:申請人須有中華民國國籍

  2. 年齡:民國73年1月1日(含)後出生者。

  3. 學經歷:不限,但須對欲申請之海外企業及其須具備之技術能力有相當程度的認識,具發展潛力及自我挑戰之企圖心,並於申請時詳細說明並提出相關證明。

  4. 英文能力:能與母語人士在研習環境及生活上流暢對談及表達之英文能力程度,並於申請時檢附英語系國家學士或同等級以上之學歷證明,或民國111年(含)後取得之英文能力證明文件之一:​

    • 多益 785分或以上

    • 托福紙本測驗(ITP) 543分 / 網路測驗(iBT) 72分或以上

    • 雅思 5.5分或以上

    • 全民英檢 中高級或以上

    • (考量英文程度評估之有效期間,若非111年後取得者,請盡速進行測驗,並於報名截止期限前繳交成績證明

  5. 具有主動積極、獨立思考與作業能力,能與團隊充分溝通合作,且勇於與不同文化、技術背景的專業人才進行交流,對於將所學有服務熱忱,且可實際貢獻臺灣產業者。

  6. 曾參與國科會產學研鏈結中心計畫(價創計畫)、研發成果萌芽計畫(萌芽計畫)、科研創業案源發掘及育成推動計畫(科創計畫)、創新創業激勵計畫(FITI計畫)等國科會科研創業相關計畫者尤佳。


四、申請方式

 

  1. 申請人須至計畫網站線上申請,報名系統網址:https://applyxtalent.stpi.narl.org.tw/xtalent/index

  2. 請務必於報名截止日期前於報名系統送出,逾期不受理。

  3. 請依線上系統登錄格式內容,詳實完整填寫中英文資料並檢附相關證明文件。

  4. 申請人須覓兩位推薦人,並於報名系統如實填寫推薦人聯絡資訊,本計畫辦公室將請推薦人協助確認相關資訊。

  5. 網路報名資料一經送出不得修改,請務必確認申請內容是否已完整填寫並附上所有附件。
     


五、甄選程序與審查方式

 

  • 報名申請
    申請人於申請時,須選擇1個或多個欲前往之海外公司研習志願,於線上系統提交中英文構想書,並針對選擇的第1研習志願提出研習構想。
  • 三階段審查
    為使甄選流程公平公正,本計畫之各階段甄選,將由本計畫辦公室邀請相關領域專家及企業代表組成「評選委員會」進行甄選。
    1. 構想書審查
      公告構想書審查結果後,將通知通過審查者培訓與選訓活動細節與研習計畫書審查資訊。
       
    2. 培訓與選訓
      通過構想書審查的候選人方獲得參與本計畫辦理之培訓與選訓資格,候選學員應全程參與選訓,於活動期間建立創新創業人脈、學習提案規劃與產業分析,並逐步完成研習計畫書。
       
    3. 研習計畫書審查
      以欲申請之研習志願為主軸,依指定之格式完成英文研習計畫書,並於計畫辦公室規定之期限內繳交。
       
  • 海外公司面試
    通過研習計畫書審查的候選人,得與通過研習計畫書之研習志願公司進行面試,並視需要進行電話或視訊訪談。本梯次面試時程依本計畫辦公室公告為主。
  • 核定公告
    本梯次實際核定學員人數將於海外公司面試結果與審查會議決定。獲選學員與本計畫辦公室簽訂合約後,將由本計畫辦公室協助簽證申請事宜,前往海外研習單位參加研習計畫。
上述程序如有異動,請依本計畫辦公室公告為主。
 

六、補助方式

 

  1. 補助金額:
    本計畫補助學員赴外研習期間之生活費,補助金額以新臺幣150萬元為原則,國外研習期間少於1年者,按比例發放。(請務必於行前衡量研習地區之消費水準與個人消費習慣)
  2. 前項補助生活費之核發分兩期撥付:
    • 第一期:第1至第6個月之補助生活費。雙方於簽訂合約且學員完成補助生活費請領手續後,於雙方約定之補助起始日前後30個日曆天內,將第一期補助生活費匯入學員指定之本人國內帳戶。
    • 第二期:第7至第12個月之補助生活費。學員應依本計畫辦公室規定時程內繳交期中自評表,經本計畫辦公室依研習單位之期中考核文件考核通過後,始撥付第二期補助生活費至學員指定之本人國內帳戶。

七、權利義務

 

  1. 本計畫為國科會為補助臺灣人才赴外研習之計畫,故優先補助取得本國學歷及未曾受領政府公費補助出國之申請人,且曾受本計畫補助者不得再次申請。

  2. 公告入選之學員赴海外研習前,須參與行前培訓及團隊凝聚活動,並與本計畫辦公室簽署合約。若無法完成合約簽署或者主動放棄簽署,視同放棄參與海外研習權利。

  3. 入選學員除應履行本計畫簡章之相關事項外,亦應確實遵守雙方簽署之合約與國科會相關規定。

  4. 入選學員於簽署合約時,應覓具中華民國國民身分之連帶保證人一人,並配合辦理對保。連帶保證人須符合以下兩個條件之一,於簽約時提供相關證明文件:(1)於我國現職服務機構服務2年以上且最近之全年薪資所得在60萬元以上(2)具有公告現值250萬元以上並位於我國之不動產所有權。另,已擔任本計畫學員連帶保證人且尚未解除或履行完擔保責任者,不得參加本計畫培訓。

  5. 前項連帶保證人若有下列情形之一,不得擔任學員之連帶保證人:(1)領取政府各類公費獲獎學金赴國外進修且尚未完成返國義務者(2)具有雙或多重國籍者(3)學員之配偶。

  6. 由於入選學員赴海外研習作業受簽證作業時程影響,確切赴海外時間依據入選學員之入境簽證文件為準,至遲須於本計畫辦公室公告之時程內抵達選定之海外研習機構。

  7. 入選學員赴海外研習若受簽證影響,無法取得本計畫規範之簽證赴外研習,恕不補助。如有特殊情況,請先知會計畫辦公室並徵得同意,計畫辦公室保留最終解釋和決定權。

  8. 學員於本計畫赴外研習期間,不得從事與研習目的無關之活動(包含原職)。若因故無法繼續參與本計畫之研習,除經本計畫辦公室書面同意外,須依合約負返還已受領之費用及相關賠償責任。

  9. 學員於本計畫赴外研習期間內應於指定期間內依規定繳交期中自評表及期末報告,並通過審查(報告格式、內容,依本計畫辦公室公告為主)。如學員報告未通過期中考核或期末報告審查,須依合約返還生活補助費並終止研習。

  10. 本計畫係國科會補助之研習計畫,國科會保留計畫執行方式與執行與否之最終決定權,包含但不限於本計畫辦公室配合國科會因天災、傳染病或其他不可抗力之事由或基於其他政策考量下片面終止本計畫。

  11. 獲本計畫補助之學員應負擔返國義務,返國義務包含返國服務、計畫宣傳義務與配合計畫辦公室後續追蹤,學員應於研習結束後5年內完成。其中返國服務之年限必須與所受領補助期限相同,計畫宣傳義務及後續追蹤內容依計畫辦公室公告為主。如完成研習之學員無法完成前述義務,本計畫保留請求全額生活補助費用、研習費用及損害賠償求償之權利。

  12. 國科會或本計畫辦公室不為結束研習之學員安排工作,學員須自行洽談覓職事宜。

  13. 其他學員權利義務以合約規範內容為準。


八、其他注意事項

 

1.本計畫之相關資訊與公告請密切注意本計畫網站:
   https://xtalent.stpi.narl.org.tw/index
   聯絡窗口:財團法人國家實驗研究院科技政策研究與資訊中心產業創新人才海外培訓計畫辦公室
   聯絡電話:02-2737-7664、(02)2737-7426
   電子信箱:xtalent@narlabs.org.tw​

   聯絡地址:10636臺北市和平東路二段106號14樓

2.本計畫簡章如有未盡事宜,本計畫辦公室及國科會隨時保留修訂公布及解釋之權利。

本計畫招生說明簡報 

X Talent 2024 1st Batch Host Companies List
查詢
AI Ventures Management, LLC

AI Fund is a startup studio building new AI companies from the ground up. Our companies bridge AI technology and applications, focusing on industries and problems that we believe move the world forward. Founded by Dr. Andrew Ng, our team merges a deep understanding of AI technology with a proven ability to start new ventures. AI Fund is uniquely positioned to build AI businesses that can make an immediate and decisive impact.

Algen Biotechnologies, Inc.

Algen, a venture-backed preclinical stage biotech company, is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer and diseases with high unmet needs. Originated from UC Berkeley, Algen is the first to elegantly fuse high throughput, wide-scale gene editing and state-of-the-art machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen’s research group focuses on developing and applying novel functional genomics technologies to address scientific challenges in drug discovery and deliver innovative, patient-centric medicines for the toughest-to-treat diseases.

 

AcuraStem Inc.

AcuraStem is a near-to-clinic, patient-based, biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

Apeximmune Therapeutics Inc.

Apeximmune Therapeutics seeks to harness the power of the immune system to treat and cure cancer. We discover and pioneer innovative therapeutic antibodies against novel targets to modulate immune cell activity and elicit durable efficacy in cancer. Apeximmune’s target discovery platform combines bioinformatics with biological assays to enable identification of novel immune modulating targets. Currently, antibodies for two immuno-oncology target programs in the pre-clinical stage are being actively developed with the goal of reaching IND status within 18 months.

Amgen Inc.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief—and the core of our strategy—is that innovative, highly differentiated medicines provide large clinical benefits in addressing serious diseases. And we believe these medicines not only help patients, but also help reduce the social and economic burden of disease in society. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Adesso Inc.

Founded in 1994, Adesso has become a design manufacturer of commercial computer peripherals, surveillance devices and vehicle accessories. We are also one of main leading TAA compliant vendors for US government organizations, schools, and Fortune 500 corporations. For TD-Synnex and Ingram Micro (Top 1 & 2 distributors globally), we are top 3 vendor of commercial computer peripherals after Logitech & Microsoft. Beside looking towards tomorrow’s pioneering designs and technology to ensure to be a leading provider, we also serving our best to each customer. 

BioLegend, Inc.

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value and with superior customer and technical support.

Chain Reaction Ltd.

Chain Reaction is engineering the future of disruptive blockchain and privacy technologies. We accelerate compute performance, enabling companies to adopt and scale solutions to the world’s most complex problems. Partnering with cloud and data centers, we transform compute infrastructure with custom ASICs and systems that optimize for energy efficient, high-performance compute. Our Privacy Processor dramatically accelerates real-time operations of Privacy Enhancing Technologies on encrypted data, transforming the cloud into a trusted environment, enabling verticals that rely on confidential big data to use the cloud (including financial institutions, healthcare & big pharma, defense & government, and oil & gas). Purpose-built and custom-designed, our solutions power the next generation of secure, scalable, green computing to help protect people, privacy, and the planet.

Delta Electronics India Pvt. Ltd.

Delta, founded in 1971, is a global provider of power and thermal management solutions. Its mission statement, To provide innovative, clean and energy-efficient solutions for a better tomorrow, focuses on addressing key environmental issues such as global climate change. As an energy-saving solutions provider with core competencies in power electronics and automation, Delta's business categories include Power Electronics, Automation, and Infrastructure.

Eos BioInnovation, LLC

Eos BioInnovation incubates and invests in projects in the field of regenerative medicine (e.g., cell & gene therapy, tissue engineering & biomaterials, molecules promoting endogenous regeneration mechanisms or helping to stop or reverse the body's degeneration processes and enabling technologies along the value chain that accelerate regenerative medicine applications) primarily from the Harvard and Boston biotech ecosystem, as well as from other top academic and research institutions. 

We are financially supported by our primary institutional partner, Panacea Venture, a $600M+ investment firm focused on healthcare investments.  We have already made two investments from the Harvard network (a neuromodulation startup from Boston Children’s Hospital and a T cell reconstitution company from Mass General Hospital/Paulson School of Engineering & Applied Science) and one investment from the University of California San Francisco (an early stage senolytics startup leveraging novel immune approaches to address age-related diseases to improve human health span).  We continue to look for exciting early stage biotech projects and are particularly interested in company formation opportunities where we launch promising companies with leading scientists and motivated entrepreneurs.

EverFocus Electronics Corporation

EverFocus is founded in 1995, a leading expert in security systems for over 28 years. Recently, our company has expanded into a new area, Smart AIoT solutionis and goal to be a world-class leader in AIoT applications such as AI smart city, security and transportation solutions with mainly produce Edge AI computers, security solutions.  EverFocus Electronics Corp offers comprehensive system integration, hardware, software, customer-centric design services, and global logistics support.  

EverFocus owned ISO9001, ISO14001 certifications; joined Intel IPA as Gold Tier member in 2020; joined the NVIDIA Preferred Partner in 2021, and has obtained Microsoft Azure service certifications for industrial computer products.

EverFocus industrial computer products have won awards such as Taiwan Excellence and COMPUTEX d&i Award. EverFocus is the most watched dark horse enterprise in the global IPC industry.

We provide a variety of customized smart solutions to help our customers and partners guard their working environment, such as: smart transportation, smart buildings, and smart security. Products are suitable for multiple vertical markets, such as commercial fleets, shopping malls, campuses and other large-scale fields.

Gradiant

The Centro Tecnolóxico de Telecomunicacións de Galicia -Gradiant was born in December 2007 with the aim of aligning university R&D with business demands.  To achieve this, throughout its history it has focused on applied research and the transfer of knowledge in information and communication technologies (ICT) to industry. The centre's priority is to help companies to generate business by providing them with tailor-made technological solutions, through capabilities concentrated in three major technological areas of specialisation: connectivity, security and intelligence. The researchers and other professionals who work in these areas are Gradiant's main resource for providing its clients - SMEs and large companies - with innovative technologies capable of increasing their competitiveness. Within the framework of these technological areas, the R&D&I activity of the centre comprises several lines of work that currently converge in: Multimedia analysis; Data analytics and big data; IoT and embedded systems; Security and privacy; and (Sub)communications systems. It is important to note that in the convergence process two distinct lines at the beginning of the 2017-2021 period, Cloud and eHealth, have been integrated into the current Data analytics and big data line. In the case of Cloud, as a sub-line of infrastructure.  For eHealth, as a sub-line called Health intelligence. During the period 17-21, Gradiant strengthens its position as a benchmark in R&D in its three main technological areas of specialisation.

Genentech Inc.

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 45 years.

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 45 years.

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

InoBat Auto j.s.a.

InoBat Auto specialises in the pioneering research, development, manufacture, and provision of premium innovative electric batteries custom-designed to meet the specific requirements of global mainstream and specialist OEMs within the automotive, commercial vehicle, motorsport, and aerospace sectors. A European based battery manufacturer, InoBat already has a battery research and development facility and pilot line under development in Slovakia. InoBat is backed by a strong consortium of investors and technology companies,  including strategic investors and partners such as Rio Tinto, CEZ, Ideonomics, Amara Raja, IPM, Matador, AEN, MSM Group. InoBat has also approved for grant financing under the EU sponsored programme, Important Projects for Common European Interest, and already received a grant from the Slovak Government.
 

Battery Academy is an educational campaign powered by InoBat, which aims to increase awareness of the battery ecosystem among students, graduates, young professionals, battery enthusiasts and others. 
 https://thebatteryacademy.com/

Instant NanoBiosensors BV.

Instant NanoBiosensors (INB) is an innovative life sciences company that has developed next generation, cost-effective ultra-sensitive real-time immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platform , Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies with 35+ global patents ( US, UK, Europe, China, Japan and Taiwan) for the life science research and in vitro diagnostics markets enables customers to reliably detect protein biomarkers in extremely low concentrations (5 orders) in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry or other capital instrument . The business opportunity includes co-development, method technology transfer, technology licensing, and IVD applications. We hope to build more strategic partnership with international associates to achieve the mission of FOPPR inside.

We are executing a multinational innovation program, called as “UREKA GlobalStars Taiwan digital industrial collaborations”, in partnership with Centre for Process Innovation (CPI), a British technology and innovation social enterprise, for the purpose of enabling UK industrial digital companies to access, collaborate with and find new markets in Taiwan. Meanwhile, we are in collaboration with global research institutes including Stanford medical center, Brigham and Women's Hospital, Amsterdam UMC, New Castle and University College London in healthcare field. This can help us to provide the information of third-party verification of our technology to pharmaceutical companies so that we can accumulate our capability abundantly for future out-licensing transaction. 

Maxzone Auto Parts Corp.

Maxzone Auto Part Corp. is the North American distribution point of DEPO products. As a leading aftermarket parts supplier, DEPO originated from a small town in central Taiwan. The brand name contains the spirit of its originality and this has inspired the core value of DEPO - Honest, humble, and hard-working.
With more than four decades of experience in R&D and manufacturing, you can count on us to bring you the highest standard products with the most value.

Mucker Capital

Mucker Capital started about 10 years ago and has grown from an accelerator to cover everything from pre-seed to series A investments, including Honey (acquired by PayPal for $4B), ServiceTitan (last valued at $9.5B), and Emailage (acquired by LexisNexis parent RELX for $500M). As one of the top early-stage venture Capital firms in the US, Mucker's portfolio companies have raised a total $8 billion in additional outside funding.

ONYX Healthcare USA, Inc.

Onyx Healthcare USA is a subsidiary of the ASUS Computer Group that has been providing innovative and medically certified (CE/FCC Class B, UL/EN60601, CSA) healthcare computing solutions to assist workflows in operating suites, nursing stat ions, patient wards, ambulatory care, and hospital administrations worldwide. Onyx Healthcare USA, Inc., with 15+ years of medical design experiences, leverages embedded computing technology to design and manufacture medical grade (UL60601-1) fanless all-in-one panel PC system platforms and embedded boards as the building blocks to medical device OEM and healthcare IT business.

Oculus BioMed Limited

Oculus BioMed Limited (OBM) is developing the next-generation standard of ocular therapies, which are designed to better preserve and improve vision in patients with retinal and cornea disorders including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

While many biotech companies pursue a single scientific platform, we are strategically building a deep and diverse pipeline of genetic therapies, novel small peptide drugs and advanced medical devices.

OBM is developing the next-generation standard of ocular therapies, which are designed to better preserve and improve vision in patients with retinal and cornea disorders including diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD).

We are a pre-clinical and clinical stage ocular company developing a pipeline of advanced therapeutics based on our proprietary OBM-1701 synthetic peptide for wAMD, OBM-17XX for dry eye disease (DED) and cornea replacement technology.

Moreover, OBM has partnered with world leading research institute – The Centre for Eye Research Australia (CERA) to develop "SwitchGene" eye gene therapies including but not limited to its potential use in treating diabetic retinopathy (DR).

Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City in 1849 in New York. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues. In 2020, 52% of the company's revenues came from the United States, 6% came from each of China and Japan, and 36% came from other countries.

PharmaEssentia Innovation Research Center

PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking.
Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today we are listed on the Taipei Exchange (TPEx: 6446) and are expanding our global presence with operations in the U.S., Japan, China and Korea, along with a world-class biologics production facility in Taichung, Taiwan.
In order to continue our mission to create better medicines, PharmaEssential plans to launch a US R & D center, named PharmaEssentia Innovation Research Center (PIRC) in 2023. PIRC laboratory and office space is currently under construction. The scheduled completion date is in June/July, 2023.
 

Polaris Electro-Optics

At Polaris Electro-Optics, Inc., we believe that overcoming society’s greatest challenges requires mastery of the creation, movement, and use of information. We are mastering the movement of information by leveraging patented material and design innovations to offer the highest-speed, most energy efficient integrated photonics products to the communications and computation industries. Our goal is to define the standard for moving information. We work hard in a collaborative, cross-functional team environment, and value mutual trust and respect built on a foundation of integrity, transparency, consistency, and humility. Additional information about Polaris is available at www.PolarisEO.com.

Taiwania Capital Management USA, Inc.

Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth.

We focus on investing in early-stage companies and have managed six funds till 2022.

We focus on financial returns, but more than that, by linking technology and capital, we aspire to create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation. 

Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Taboola

Taboola helps people find relevant content online, matching them with news stories, articles, blogs, videos, apps, products and other content they’re likely to want to explore.
How do we know what they’ll like? Using machine-learning algorithms, our technology analyzes hundreds of signals to capture exactly what kind of content is most likely to engage each individual. We do that more than 450 billion times a month for more than one billion unique users.

Since we opened our doors in 2006, we have grown to become the leading discovery platform on the open web, serving a combination of the world’s best brands and the most respected global publishers.

Taboola is headquartered in New York City with local offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, São Paulo, Beijing, Shanghai, Istanbul, Seoul, Sydney, Tokyo and Taiwan.

Tubis Technology Inc.

Tubis Technology Inc. is a leading technology developer for mmWave 5G NR technology. We develop  mmWave beamforming transceiver IC for phased-array antenna and the ORAN based FR2 base station.

Vizuro LLC

Vizuro is an innovator and solution provider of Multimodal, Causal AI with its powerful applications in diverse sectors. We utilize our proprietary self-learning, explainable and actionable AI on a managed, data-science-as-a-service platform to quickly deploy bespoke applications in an expedited timeframe. We serve global clients in various sectors and sizes, ranging from Fortune 100 enterprises to startups.

ZalaZONE Industrial Park Ltd.

The ZalaZONE Industrial Park Ltd., through its ZalaZONE trainee programme, aims to contribute to the provision of labour mobility for the companies operating in the park and for the new enterprises, in co-operation with ZalaZONE Research & Technology Center and the available university research groups.  One of the aims of the programme is to create a space for cooperation between industrial and economic players and the university sector, and to promote cooperation between the partners. 
The focus is on creating an internationally high-quality education and research environment with high added value for the region's competitiveness. 
The engineers working in the various laboratories and workshops, as well as the partners coming to the park, will seek R&D and technical solutions to emerging industrial problems and challenges in areas such as:
automotive development, testing and validation, mechatronics, software and communication systems development, engineering and product design, manufacturing and materials technologies.

more
back to top